Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 30:5:2797.
doi: 10.12688/f1000research.9272.1. eCollection 2016.

Understanding nontuberculous mycobacterial lung disease: it's been a long time coming

David E Griffith  1 , Timothy R Aksamit  2
Affiliations
Review

Understanding nontuberculous mycobacterial lung disease: it's been a long time coming

David E Griffith et al. F1000Res. .

Abstract

With a surprising predictability, most studies and reviews addressing therapy for nontuberculous mycobacterial (NTM) lung disease either start or end by mentioning the paucity of data from randomized and controlled trials. That is a legitimate criticism for NTM lung disease therapy, but it also somehow seems to influence attitudes toward all aspects of NTM investigation. Certainly the study of NTM diseases in general and NTM lung disease in particular is a recent development. Previously, NTM were viewed as minor, if inconvenient, pathogens similar to Mycobacterium tuberculosis. However, over the last three decades, NTM have emerged as increasingly important pathogens that are clearly different compared with tuberculosis. Although there has been frustratingly slow progress in the treatment of NTM diseases, in contrast there has unquestionably been impressive progress in almost every other realm of investigation into NTM disease. Our understanding of NTM lung disease a) pathophysiology, including mechanisms of organism acquisition, b) epidemiology, including estimates of disease prevalence, c) mycobacteriology, including application of molecular laboratory techniques and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, and d) even treatment strategies, including the recognition of innate drug resistance mechanisms, has immeasurably and permanently changed and advanced the landscape for NTM lung disease. It is no longer necessary to apologize for the state of NTM lung disease knowledge and understanding, but rather it is time to recognize the great distance we have travelled over the last 30 years.

Keywords: Nontuberculous; lung disease; mycobacterial.

PubMed Disclaimer

Conflict of interest statement

The authors have no real or potential conflicts of interest to declare. No competing interests were disclosed. No competing interests were disclosed. No competing interests were disclosed. No competing interests were disclosed.

References

    1. Adjemian J, Prevots DR, Gallagher J, et al. : Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9–16. 10.1513/AnnalsATS.201304-085OC - DOI - PMC - PubMed
    1. Runyon EH: Typical myobacteria: their classification. Am Rev Respir Dis. 1965;91:288–9. - PubMed
    1. Runyon EH: Identification of mycobacterial pathogens utilizing colony characteristics. Am J Clin Pathol. 1970;54(4):578–86. 10.1093/ajcp/54.4.578 - DOI - PubMed
    1. Wolinsky E: Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979;119(1):107–59. - PubMed
    1. Wallace RJ, O'Brien R, Glassroth J, et al. : Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis. 1990;142(4):940–53. 10.1164/ajrccm/142.4.940 - DOI - PubMed